We have argued for many years that supporting patient access to innovation will in turn support the pharmaceutical industry and make the UK a more attractive place for our industry to do business.
This is becoming more important as the international arena becomes more competitive and the traditional ‘big pharma’ model becomes something far more fluid.
Government’s support for our industry is a significant step to opening up the NHS to research – this will make the UK a more inviting place to locate research and, therefore, investment. Ultimately, this leads to a better service for patients. As the Prime Minister recognises, the NHS thrives on innovation and specifically that innovation – when utilised – not only delivers patient outcomes, but can also be a key driver of long-term growth for the UK economy and for the life sciences sector.
We welcome a number of elements from today’s announcement, including:
In summary, we welcome the support for the whole life science ecosystem; including the gap funding for early stage research and SMEs. As the pharmaceutical industry comes under new global pressures, the survival of the sector is reliant on this health ecosystem and this initiative should set the UK apart as a front runner.
This launch marks a significant step forward for the life sciences industries in the UK. It is crucial that the commitments made today are made a reality in our everyday working practices, and that they are implemented quickly to maintain confidence that this marks a change in what the UK can offer industry.
Stephen WhiteheadABPI Chief Executive